Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Paul Chan, Li Shao, Brian Tomlinson, Yuzhen Zhang & Zhong-Min Liu. (2019) An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy 20:1, pages 103-113.
Read now
Read now
Dewei Shang, Shuhua Deng, Zhenhong Yao, Zhanzhang Wang, Xiaojia Ni, Ming Zhang, Jinqing Hu, Haoyang Lu, Xiuqing Zhu, Wencan Huang, Chang Qiu & Yuguan Wen. (2016) The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese male subjects. Xenobiotica 46:1, pages 34-39.
Read now
Read now
Dujrudee Chinwong, Jayanton Patumanond, Surarong Chinwong, Khanchai Siriwattana, Siriluck Gunaparn, John Joseph Hall & Arintaya Phrommintikul. (2015) Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency. Therapeutics and Clinical Risk Management 11, pages 127-136.
Read now
Read now
Ning Ma & Lianqun Cui. (2015) Comparative efficacy of pitavastatin and simvastatin in patients with hypercholesterolemia: a meta-analysis of randomized controlled clinical trials. Drug Design, Development and Therapy 9, pages 1859-1864.
Read now
Read now
Kevin W Chamberlin & William L Baker. (2015) Benefit–risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients. Clinical Interventions in Aging 10, pages 733-740.
Read now
Read now
Vivencio Barrios, Carlos Escobar & José L Zamorano. (2013) Searching the place of pitavastatin in the current treatment of patients with dyslipidemia. Expert Review of Cardiovascular Therapy 11:12, pages 1597-1612.
Read now
Read now
Ken Kishida, Tohru Funahashi & Iichiro Shimomura. (2013) Effects of pitavastatin on HDL metabolism. Clinical Lipidology 8:1, pages 55-68.
Read now
Read now
M John Chapman. (2012) Role of HDL-C as a cardiovascular risk factor: clinical relevance of pitavastatin. Clinical Lipidology 7:sup1, pages 17-24.
Read now
Read now
Alberto Corsini & Richard Ceska. (2011) Drug–drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel?. Current Medical Research and Opinion 27:8, pages 1551-1562.
Read now
Read now
Yasuyuki Kawai, Ryoko Sato-Ishida, Atsushi Motoyama & Kouji Kajinami. (2011) Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug Design, Development and Therapy 5, pages 283-297.
Read now
Read now
Jun Sasaki. (2010) Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia. Vascular Health and Risk Management 6, pages 997-1005.
Read now
Read now
Antonio M Gotto Jr & Jennifer Moon. (2010) Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia. Expert Review of Cardiovascular Therapy 8:8, pages 1079-1090.
Read now
Read now
Leiv Ose. (2010) Pitavastatin: a distinctive lipid-lowering drug. Clinical Lipidology 5:3, pages 309-323.
Read now
Read now
Tamio Teramoto, Hitoshi Shimano, Koutaro Yokote & Mitsuyoshi Urashima. (2010) New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opinion on Pharmacotherapy 11:5, pages 817-828.
Read now
Read now
Yasushi Saito. (2009) Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vascular Health and Risk Management 5, pages 921-936.
Read now
Read now
Articles from other publishers (48)
Adel Sadeq, Asim Ahmed Elnour, Farah Hamad Farah, Azza Ramadan, Mohamed A. Baraka, Judit Don, Abdulla Al Amoodi, Kishore Gnana Sam, Nadia Al Mazrouei & Maisoun Alkaabi. (2023) A Systematic Review of Randomized Clinical Trials on the Efficacy and
Safety of Pitavastatin. Current Reviews in Clinical and Experimental Pharmacology 18:2, pages 120-147.
Crossref
Crossref
Azza Ramadan & AsimAhmed Elnour. (2022) Mini-Review on the efficacy and safety of pitavastatin: “The novel seventh statin gaining momentum”. Journal of Pharmacy And Bioallied Sciences 14:2, pages 72.
Crossref
Crossref
Amirhossein Sahebkar, Nasim Kiaie, Armita Mahdavi Gorabi, Massimo R. Mannarino, Vanessa Bianconi, Tannaz Jamialahmadi, Matteo Pirro & Maciej Banach. (2021) A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Progress in Lipid Research 84, pages 101127.
Crossref
Crossref
In-Kyung Jeong & Sung-Rae Kim. (2020) Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study). Endocrinology and Metabolism 35:4, pages 882-891.
Crossref
Crossref
Woong Chol Kang, Minsu Kim, Sang Min Park, Byeong-Keuk Kim, Byoung-Kwon Lee & Hyuck Moon Kwon. (2020) Preventive Effect of Pretreatment with Pitavastatin on Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Procedure: PRINCIPLE-II Randomized Clinical Trial. Journal of Clinical Medicine 9:11, pages 3689.
Crossref
Crossref
Stephen P Adams, Nima Alaeiilkhchi & James M Wright. (2020) Pitavastatin for lowering lipids. Cochrane Database of Systematic Reviews 2020:7.
Crossref
Crossref
Xiaodan Zhang, Lu Xing, Xiaona Jia, Xiaocong Pang, Qian Xiang, Xia Zhao, Lingyue Ma, Zhiyan Liu, Kun Hu, Zhe Wang & Yimin Cui. (2020) Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. Cardiovascular Therapeutics 2020, pages 1-21.
Crossref
Crossref
Turki A. Althunian, Anthonius de Boer, Rolf H.H. Groenwold & Olaf H. Klungel. (2018) Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. Journal of Clinical Epidemiology 104, pages 15-23.
Crossref
Crossref
A. Agarwala, S. Kulkarni & T. Maddox. (2018) The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. Current Cardiology Reports 20:7.
Crossref
Crossref
Ryuichi Ogawa. (2018) Approach to Practical Training in Basic Clinical Pharmacy for Third-Year Pharmacy Students: Literature Appraisal and Professional Writing薬学部3年生に対する臨床薬学基礎実習の取り組み：文献評価とプロフェッショナル・ライティング. YAKUGAKU ZASSHI 138:5, pages 637-644.
Crossref
Crossref
Sandeep Kumar, Bhoomika Sharma, Priyanka Bhadwal, Prerna Sharma & Navneet Agnihotri. 2018. Therapeutic Foods. Therapeutic Foods
51
98
.
Hun‐Sung Kim, Hyeseon Lee, Sue Hyun Lee, Yoo Jin Jeong, Tong Min Kim, So Jung Yang, Sun Jung Baik, Hyunah Kim, Seung‐Hwan Lee, Jae Hyoung Cho, In‐Young Choi, Kun‐Ho Yoon & Ju Han Kim. (2017) Use of Moderate‐Intensity Statins for Low‐Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans. Basic & Clinical Pharmacology & Toxicology 121:4, pages 272-278.
Crossref
Crossref
M. G Bubnova. (2017) Modern opportunities for lifestyle changes and statin therapy in the prevention of cardiovascular diseases. CardioSomatics 8:3, pages 39-4.
Crossref
Crossref
Angela Pirillo & Alberico L. Catapano. (2017) Pitavastatin and HDL: Effects on plasma levels and function(s). Atherosclerosis Supplements 27, pages e1-e9.
Crossref
Crossref
Y. J. Jeong, H. Kim, S. J. Baik, T. M. Kim, S. J. Yang, S.-H. Lee, J.-H. Cho, H. Lee, H. W. Yim, I. Y. Choi, K.-H. Yoon & H.-S. Kim. (2017) Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea. Journal of Clinical Pharmacy and Therapeutics 42:3, pages 292-300.
Crossref
Crossref
Sheridan M. Hoy. (2017) Pitavastatin: A Review in Hypercholesterolemia. American Journal of Cardiovascular Drugs 17:2, pages 157-168.
Crossref
Crossref
Divyesh Thakker, Sunita Nair, Amit Pagada, Vinayak Jamdade & Anuradha Malik. (2016) Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiology and Drug Safety 25:10, pages 1131-1149.
Crossref
Crossref
Vivencio Barrios & Carlos Escobar. (2016) Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes. Future Cardiology 12:4, pages 449-466.
Crossref
Crossref
H.-S. Kim, H. Kim, H. Lee, B. Park, S. Park, S.-H. Lee, J. H. Cho, H. Song, J. H. Kim, K.-H. Yoon & I. Y. Choi. (2016) Analysis and comparison of statin prescription patterns and outcomes according to clinical department. Journal of Clinical Pharmacy and Therapeutics 41:1, pages 70-77.
Crossref
Crossref
Marjet J.A.M. Braamskamp, Claudia Stefanutti, Gisle Langslet, Euridiki Drogari, Albert Wiegman, Neil Hounslow & John J.P. Kastelein. (2015) Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. The Journal of Pediatrics 167:2, pages 338-343.e5.
Crossref
Crossref
Antonio J. Vallejo-Vaz, Sreenivasa Rao Kondapally Seshasai, Kazumasa Kurogi, Ichiro Michishita, Tsuyoshi Nozue, Seigo Sugiyama, Sotirios Tsimikas, Hiroshi Yoshida & Kausik K. Ray. (2015) Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 241:2, pages 409-418.
Crossref
Crossref
Antonio M. Gotto & Jennifer E. Moon. 2015. Dyslipidemias. Dyslipidemias
403
421
.
Zhen Jiang, Ren Rong Gong, Li Qiu, Qian Wang, Mi Su, Xiao Juan Liu, Min Shan Hu, Jia Lin & Ding Zhi Fang. (2014) Efficacy and Safety of Pitavastatin Versus Simvastatin: A Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation 34:9, pages 599-608.
Crossref
Crossref
Craig A. Sponseller, Roger E. Morgan, Vladimir A. Kryzhanovski, Stuart E. Campbell & Michael H. Davidson. (2014) Comparison of the Lipid-Lowering Effects of Pitavastatin 4 mg Versus Pravastatin 40 mg in Adults With Primary Hyperlipidemia or Mixed (Combined) Dyslipidemia: A Phase IV, Prospective, US, Multicenter, Randomized, Double-blind, Superiority Trial. Clinical Therapeutics 36:8, pages 1211-1222.
Crossref
Crossref
Marilyne Brault, Jessica Ray, Yessica-Haydee Gomez, Christos S. Mantzoros & Stella S. Daskalopoulou. (2014) Statin treatment and new-onset diabetes: A review of proposed mechanisms. Metabolism 63:6, pages 735-745.
Crossref
Crossref
Benoit Chauvin, Sylvain Drouot, Aurélie Barrail-Tran & Anne-Marie Taburet. (2013) Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors. Clinical Pharmacokinetics 52:10, pages 815-831.
Crossref
Crossref
Katherine A. Lyseng-Williamson & Sean T. Duggan. (2012) Pitavastatin: a guide to its use in hypercholesterolaemia and mixed dyslipidaemia. Drugs & Therapy Perspectives 28:9, pages 5-9.
Crossref
Crossref
T. Barry Levine & Arlene B. Levine. 2012. Metabolic Syndrome and Cardiovascular Disease. Metabolic Syndrome and Cardiovascular Disease
347
408
.
Jennifer Santee, Cameron Lindsey & Heather Pace. (2012) Relative Efficacy of Antilipemic Agents in Non–High-Density Lipoprotein Cholesterol Reduction. Journal of Pharmacy Practice 25:4, pages 447-456.
Crossref
Crossref
Roger E. Morgan, Stuart E. Campbell, Christine Y. Yu, Craig A. Sponseller & Heather A. Muster. (2012) Comparison of the Safety, Tolerability, and Pharmacokinetic Profile of a Single Oral Dose of Pitavastatin 4 mg in Adult Subjects With Severe Renal Impairment Not on Hemodialysis Versus Healthy Adult Subjects. Journal of Cardiovascular Pharmacology 60:1, pages 42-48.
Crossref
Crossref
N. Poolsup, N. Suksomboon, K. Wongyaowarat, B. Rungkanchananon, P. Niyomrat & S. Kongsuwan. (2012) Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. Journal of Clinical Pharmacy and Therapeutics 37:2, pages 166-172.
Crossref
Crossref
Jean Davignon. (2012) Pleiotropic effects of pitavastatin. British Journal of Clinical Pharmacology 73:4, pages 518-535.
Crossref
Crossref
Sean T. Duggan. (2012) Pitavastatin. Drugs 72:4, pages 565-584.
Crossref
Crossref
Giampietro Viola, Pawel Grobelny, Maria Antonella Linardi, Alessia Salvador, Stefano Dall’Acqua, Łukasz Sobotta, Jadwiga Mielcarek, Francesco Dall’Acqua, Daniela Vedaldi & Giuseppe Basso. (2011) Pitavastatin, a new HMG-CoA reductase inhibitor, induces phototoxicity in human keratinocytes NCTC-2544 through the formation of benzophenanthridine-like photoproducts. Archives of Toxicology 86:3, pages 483-496.
Crossref
Crossref
Ulrich Schwabe & Dieter PaffrathUlrich Schwabe & Uwe Fricke. 2012. Arzneiverordnungs-Report 2012. Arzneiverordnungs-Report 2012
43
126
.
Tamio Teramoto. (2011) Pitavastatin: Clinical effects from the LIVES Study. Atherosclerosis Supplements 12:3, pages 285-288.
Crossref
Crossref
M. John Chapman. (2011) Pitavastatin: Novel effects on lipid parameters. Atherosclerosis Supplements 12:3, pages 277-284.
Crossref
Crossref
Yasushi Saito. (2011) Pitavastatin: An overview. Atherosclerosis Supplements 12:3, pages 271-276.
Crossref
Crossref
Steve Warrington, Shunji Nagakawa & Neil Hounslow. (2011) Comparison of the Pharmacokinetics of Pitavastatin by Formulation and Ethnic Group. Clinical Drug Investigation 31:10, pages 735-743.
Crossref
Crossref
Laurie L. Yee & Eric A. Wright. (2011) Pitavastatin Calcium: Clinical Review of a New Antihyperlipidemic Medication. Clinical Therapeutics 33:8, pages 1023-1042.
Crossref
Crossref
Pedro Marques da Silva. (2011) Are All Statins the Same?. American Journal Cardiovascular Drugs 11:2, pages 93-107.
Crossref
Crossref
Leiv Ose. (2011) Pitavastatin: finding its place in therapy. Therapeutic Advances in Chronic Disease 2:2, pages 101-117.
Crossref
Crossref
Yasushi WakidaSatoshi SuzukiHirohiko Nomura, on behalf of APPROACH-J InvestigatorsTatsuya Isomura. (2011) Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study). Japanese Clinical Medicine 2, pages JCM.S7863.
Crossref
Crossref
Yasushi Saito. (2011) Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6565.
Crossref
Crossref
Luís Masana. (2010) Pitavastatin – from clinical trials to clinical practice. Atherosclerosis Supplements 11:3, pages 15-22.
Crossref
Crossref
John Betteridge. (2010) Pitavastatin – results from phase III & IV. Atherosclerosis Supplements 11:3, pages 8-14.
Crossref
Crossref
Alberico L. Catapano. (2010) Pitavastatin – pharmacological profile from early phase studies. Atherosclerosis Supplements 11:3, pages 3-7.
Crossref
Crossref
Leiv Ose, Dragos Budinski, Neil Hounslow & Valerie Arneson. (2010) Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 210:1, pages 202-208.
Crossref
Crossref